Education
About Us
Working with TipRanks
Follow Us
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H (HK:0874)
:0874
0874 Stock Chart & Stats
HK$18.75
-HK$0.10(-0.58%)
At close: 4:00 PM EST
HK$18.75
-HK$0.10(-0.58%)
Day’s Range― - ―
52-Week RangeHK$15.76 - HK$20.40
Previous CloseN/A
Volume792.44K
Average Volume (3M)908.48K
Market Cap
HK$44.16B
Enterprise ValueHK$47.91B
Total Cash (Recent Filing)HK$18.33B
Total Debt (Recent Filing)HK$20.79B
Price to Earnings (P/E)9.7
Beta0.64
Next Earnings
Mar 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.15%
Share Statistics
EPS (TTM)0.55
Shares Outstanding219,900,000
10 Day Avg. Volume928,235
30 Day Avg. Volume908,476
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)0.77
Price to Sales (P/S)0.37
P/FCF Ratio12.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Product Portfolio & DistributionA broad product mix spanning prescription drugs, OTC medicines and TCM plus established distributor and healthcare partnerships supports stable revenue streams and lowers reliance on any single product. This diversification helps sustain sales across cycles and geographic channels over months.
Sizable Equity Base And Positive ROEA meaningful equity buffer and positive return on equity provide financial resilience, enabling investment in R&D and operations without immediate reliance on external funding. This capital base supports medium-term strategic flexibility despite near-term earnings pressure.
Positive Free Cash FlowMaintaining positive free cash flow indicates underlying cash generation after capital spending, supporting dividends, capex and selective investments. While coverage weakened, persistent FCF provides a structural cushion for financing needs over the coming quarters if trends stabilize.
Bears Say
Negative Operating Cash FlowA TTM operating cash outflow signals deteriorating cash conversion, likely from rising working-capital needs or timing issues. Sustained negative OCF strains liquidity, forces reliance on debt or equity financing, and undermines the firm's ability to fund operations and growth over the medium term.
Rising LeverageMaterial debt growth and a higher debt-to-equity ratio reduce financial flexibility, raise interest burden risk, and constrain capacity for opportunistic investments. Higher leverage makes the company more sensitive to cash-flow volatility and could pressure credit metrics over the next several quarters.
Margin CompressionDeclining gross and net margins indicate squeeze on profitability from cost pressures or pricing mix shifts. If sustained, weaker margins erode internal funding for R&D and marketing, reduce competitiveness and limit capacity to restore prior profitability levels over the medium term.
Guangzhou Baiyunshan Pharmaceutical Holdings Company News
0874 FAQ
What was Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price range in the past 12 months?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H lowest stock price was HK$15.76 and its highest was HK$20.40 in the past 12 months.
What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap is HK$44.16B.
When is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date is Mar 21, 2026 which is in 31 days.
How were Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s earnings last quarter?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H released its earnings results on Oct 28, 2025. The company reported HK$0.552 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.552.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H overvalued?
According to Wall Street analysts Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price is currently Overvalued.
Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pay dividends?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pays a Quarterly dividend of HK$0.44 which represents an annual dividend yield of 7.15%. See more information on Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H dividends here
What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H have?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H has 219,900,000 shares outstanding.
What happened to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price movement after its last earnings report?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H reported an EPS of HK$0.552 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.332%.
Which hedge fund is a major shareholder of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H?
Currently, no hedge funds are holding shares in HK:0874
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guangzhou Baiyunshan Pharmaceutical Holdings Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.34%
12-Months-Change
Fundamentals
Return on Equity
7.86%
Trailing 12-Months
Asset Growth
7.19%
Trailing 12-Months
Company Description
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) Earnings & Revenues
Technical Analysis
The United Laboratories International Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---